Takeda Boosts European, Emerging Markets Footprint With $13.6B Nycomed Buy

Japan's largest drug maker confirms Nycomed deal, which will double its European sales, jumpstart its emerging markets presence and provide a 30% revenue boost as key drug Actos faces patent expiry.